MX2021008981A - Benzothiadiazepine compounds and their use as bile acid modulators. - Google Patents
Benzothiadiazepine compounds and their use as bile acid modulators.Info
- Publication number
- MX2021008981A MX2021008981A MX2021008981A MX2021008981A MX2021008981A MX 2021008981 A MX2021008981 A MX 2021008981A MX 2021008981 A MX2021008981 A MX 2021008981A MX 2021008981 A MX2021008981 A MX 2021008981A MX 2021008981 A MX2021008981 A MX 2021008981A
- Authority
- MX
- Mexico
- Prior art keywords
- bile acid
- compounds
- acid modulators
- diseases
- benzothiadiazepine
- Prior art date
Links
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title abstract 3
- 239000003613 bile acid Substances 0.000 title abstract 3
- KAOYLRLQZXRRBD-UHFFFAOYSA-N 1,2,3-benzothiadiazepine Chemical class S1N=NC=CC2=CC=CC=C12 KAOYLRLQZXRRBD-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 abstract 2
- 108091006614 SLC10A2 Proteins 0.000 abstract 2
- CICPSCXBPAGDJY-UHFFFAOYSA-N 1,2,5-benzothiadiazepine Chemical class S1N=CC=NC2=CC=CC=C12 CICPSCXBPAGDJY-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004129 fatty acid metabolism Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201911004690 | 2019-02-06 | ||
SE1950464 | 2019-04-12 | ||
IN201911049981 | 2019-12-04 | ||
PCT/EP2020/052942 WO2020161217A1 (en) | 2019-02-06 | 2020-02-06 | Benzothiadiazepine compounds and their use as bile acid modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021008981A true MX2021008981A (en) | 2021-09-08 |
Family
ID=69591608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021008981A MX2021008981A (en) | 2019-02-06 | 2020-02-06 | Benzothiadiazepine compounds and their use as bile acid modulators. |
Country Status (30)
Country | Link |
---|---|
US (1) | US20230406832A1 (en) |
EP (1) | EP3921028B1 (en) |
JP (1) | JP2022519370A (en) |
KR (1) | KR20210126053A (en) |
CN (1) | CN113677398A (en) |
AU (1) | AU2020218908A1 (en) |
BR (1) | BR112021015060A2 (en) |
CA (1) | CA3127568A1 (en) |
CL (1) | CL2021001934A1 (en) |
CO (1) | CO2021010400A2 (en) |
CR (1) | CR20210458A (en) |
DK (1) | DK3921028T3 (en) |
EC (1) | ECSP21056710A (en) |
ES (1) | ES2937153T3 (en) |
FI (1) | FI3921028T3 (en) |
HR (1) | HRP20230039T1 (en) |
HU (1) | HUE060905T2 (en) |
IL (1) | IL284983B1 (en) |
LT (1) | LT3921028T (en) |
MX (1) | MX2021008981A (en) |
PE (1) | PE20212251A1 (en) |
PL (1) | PL3921028T3 (en) |
PT (1) | PT3921028T (en) |
RS (1) | RS63899B1 (en) |
SG (1) | SG11202108566VA (en) |
SI (1) | SI3921028T1 (en) |
TW (1) | TW202045483A (en) |
UA (1) | UA127911C2 (en) |
WO (1) | WO2020161217A1 (en) |
ZA (1) | ZA202106472B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS55266B1 (en) | 2010-11-08 | 2017-02-28 | Albireo Ab | Ibat inhibitors for the treatment of liver diseases |
CN106659726A (en) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | Solid preparation, and method for preventing or reducing discoloration thereof |
WO2019234077A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
WO2019245449A1 (en) | 2018-06-20 | 2019-12-26 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2021110886A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20220109450A (en) | 2019-12-04 | 2022-08-04 | 알비레오 에이비 | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202134223A (en) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | Benzothia(di)azepine compounds and their use as bile acid modulators |
AR120682A1 (en) | 2019-12-04 | 2022-03-09 | Albireo Ab | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS |
AR120683A1 (en) | 2019-12-04 | 2022-03-09 | Albireo Ab | BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID |
TW202134218A (en) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | Benzothiazepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
EP4069247A1 (en) | 2019-12-04 | 2022-10-12 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
CN114786772B (en) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | Benzothiazepine compounds and their use as bile acid modulators |
JP2023537285A (en) | 2020-08-03 | 2023-08-31 | アルビレオ・アクチボラグ | Benzothia(di)azepine compounds and their use as bile acid modulators |
JP2023549226A (en) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | Odevixibat for the treatment of progressive familial intrahepatic cholestasis (PFIC) |
AU2021390172A1 (en) | 2020-12-04 | 2023-06-22 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2023164186A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164179A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164183A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164181A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
US20230338392A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI106800B (en) | 1990-12-06 | 2001-04-12 | Hoechst Ag | A process for the preparation of novel therapeutically useful dimeric bile acid derivatives |
ATE135380T1 (en) | 1991-12-20 | 1996-03-15 | Hoechst Ag | POLYMERS AND OLIGOMERS OF BALE ACID DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS |
GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
DE59307759D1 (en) | 1992-06-12 | 1998-01-15 | Hoechst Ag | Bile acid derivatives, process for their preparation and use of these compounds as medicaments |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
ZA941003B (en) | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
TW289021B (en) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
EP0624593A3 (en) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Bile acid derivates, a method for their production and their use as medicines. |
TW289757B (en) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
TW289020B (en) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
ES2155136T3 (en) | 1994-09-13 | 2001-05-01 | Monsanto Co | NEW BENZOTIEPINES THAT HAVE ACTIVITY AS INHIBITORS OF THE TRANSPORT OF ILLACO BILIAR ACID AND TAUROCOLATE CAPTURING. |
GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
DE69734100D1 (en) | 1996-03-11 | 2005-10-06 | G D Searle Llc St Louis | BENZOTHIEPINES WITH INPUT AS INHIBITORS OF ILEUMGALLIC ACID TRANSPORT AND TAUROCHOLATE RECORDING |
EP0912861B1 (en) | 1996-07-24 | 2000-11-29 | Zumtobel Staff GmbH | Adapter for a retaining means used to secure a built-in lamp in a mounting hole, or retaining means or built-in lamp provided with such an adapter |
DE19633268A1 (en) | 1996-08-19 | 1998-02-26 | Hoechst Ag | Polymeric bile acid absorption inhibitors with simultaneous bile acid adsorber action |
GB9704208D0 (en) * | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
RU2247579C2 (en) | 1997-03-11 | 2005-03-10 | Джи. Ди. Сирл Энд Ко. | Combined treatment using benzothiepins inhibiting transport of bile acid in jejunum and inhibitors of hmg-coa-reductase |
PT864582E (en) | 1997-03-14 | 2003-10-31 | Aventis Pharma Gmbh | 1,4-BENZOTIAZEPINE-1,1-DIOXIDES HIPOLIPIDEMICOS |
GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
DE19825804C2 (en) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation and medicaments containing these compounds |
CZ20012343A3 (en) | 1998-12-23 | 2001-12-12 | G. D. Searle Llc | Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
HUP0201972A3 (en) | 1998-12-23 | 2005-06-28 | G D Searle Llc Chicago | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
NZ512532A (en) | 1998-12-23 | 2003-12-19 | G | Combinations for treating cardiovascular diseases like hypercholesterolemia and atherosclerosis |
CA2356156A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications |
CN1342090A (en) | 1998-12-23 | 2002-03-27 | G·D·瑟尔有限公司 | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular disease |
CA2362147A1 (en) | 1999-02-12 | 2000-08-17 | Steve A. Kolodziej | 1,2-benzothiazepines for the treatment of hyperlipidemic diseases |
DE19916108C1 (en) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | 1,4-Benzothiazepine-1,1-dioxide derivatives substituted with sugar residues, process for their preparation and their use |
SE9901387D0 (en) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
SE0000772D0 (en) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
AU2001247331A1 (en) | 2000-03-10 | 2001-09-24 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
SE0003766D0 (en) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
BRPI0212346B1 (en) * | 2001-09-08 | 2016-02-02 | Albireo Ab | COMPOUNDS DERIVED FROM BENZOTIADIAZEPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF WITH INHIBITING EFFECTS ON THE TRANSPORTATION OF ILEAL BILE ACID, PROCESS FOR THE PREPARATION OF THE SAME, USE THEREOF, AND, PHARMACEUTICAL COMPOSITION. |
GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
AU2003257578B2 (en) | 2002-08-28 | 2009-01-22 | Asahi Kasei Pharma Corporation | Novel quaternary ammonium compounds |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
US20050215882A1 (en) | 2004-03-23 | 2005-09-29 | The Regents Of The University Of Michigan | Noninvasive method to determine fat content of tissues using MRI |
DE102005033100B3 (en) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Novel 1,4-benzothiazepine-1,1-dioxide derivative with improved properties, drugs containing this compound and methods for their preparation |
DE102005033099A1 (en) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicines containing it and its use |
US9295677B2 (en) | 2008-02-26 | 2016-03-29 | Qing Bile Therapeutics Inc. | Polyhydroxylated bile acids for treatment of biliary disorders |
JO3131B1 (en) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | Chemical Compounds |
MX2016011063A (en) | 2014-02-27 | 2016-11-30 | Nusirt Sciences Inc | Compositions and methods for the reduction or prevention of hepatic steatosis. |
KR20160061492A (en) | 2014-11-21 | 2016-06-01 | 삼성디스플레이 주식회사 | Portable dust senser and cellular phone using the same |
CN108601744B (en) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | Oral cholestyramine formulations and uses thereof |
ES2874546T3 (en) | 2016-02-09 | 2021-11-05 | Albireo Ab | Oral formulation of cholestyramine and its use |
US11350844B2 (en) | 2016-11-23 | 2022-06-07 | Mayo Foundation For Medical Education And Research | System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography |
EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
WO2019032027A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
-
2020
- 2020-02-06 FI FIEP20705305.9T patent/FI3921028T3/en active
- 2020-02-06 HU HUE20705305A patent/HUE060905T2/en unknown
- 2020-02-06 IL IL284983A patent/IL284983B1/en unknown
- 2020-02-06 JP JP2021545897A patent/JP2022519370A/en active Pending
- 2020-02-06 KR KR1020217028378A patent/KR20210126053A/en active Search and Examination
- 2020-02-06 PE PE2021001268A patent/PE20212251A1/en unknown
- 2020-02-06 BR BR112021015060-9A patent/BR112021015060A2/en unknown
- 2020-02-06 UA UAA202104946A patent/UA127911C2/en unknown
- 2020-02-06 SG SG11202108566VA patent/SG11202108566VA/en unknown
- 2020-02-06 MX MX2021008981A patent/MX2021008981A/en unknown
- 2020-02-06 PT PT207053059T patent/PT3921028T/en unknown
- 2020-02-06 PL PL20705305.9T patent/PL3921028T3/en unknown
- 2020-02-06 HR HRP20230039TT patent/HRP20230039T1/en unknown
- 2020-02-06 CN CN202080012140.4A patent/CN113677398A/en active Pending
- 2020-02-06 CA CA3127568A patent/CA3127568A1/en active Pending
- 2020-02-06 RS RS20230040A patent/RS63899B1/en unknown
- 2020-02-06 WO PCT/EP2020/052942 patent/WO2020161217A1/en unknown
- 2020-02-06 SI SI202030140T patent/SI3921028T1/en unknown
- 2020-02-06 EP EP20705305.9A patent/EP3921028B1/en active Active
- 2020-02-06 TW TW109103758A patent/TW202045483A/en unknown
- 2020-02-06 ES ES20705305T patent/ES2937153T3/en active Active
- 2020-02-06 CR CR20210458A patent/CR20210458A/en unknown
- 2020-02-06 LT LTEPPCT/EP2020/052942T patent/LT3921028T/en unknown
- 2020-02-06 DK DK20705305.9T patent/DK3921028T3/en active
- 2020-02-06 AU AU2020218908A patent/AU2020218908A1/en active Pending
-
2021
- 2021-07-22 CL CL2021001934A patent/CL2021001934A1/en unknown
- 2021-07-30 EC ECSENADI202156710A patent/ECSP21056710A/en unknown
- 2021-08-06 CO CONC2021/0010400A patent/CO2021010400A2/en unknown
- 2021-09-03 ZA ZA2021/06472A patent/ZA202106472B/en unknown
-
2023
- 2023-02-03 US US18/164,185 patent/US20230406832A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3921028B1 (en) | 2022-11-09 |
ECSP21056710A (en) | 2021-08-31 |
UA127911C2 (en) | 2024-02-07 |
AU2020218908A1 (en) | 2021-08-26 |
PT3921028T (en) | 2023-02-15 |
CA3127568A1 (en) | 2020-08-13 |
CO2021010400A2 (en) | 2021-08-19 |
ES2937153T3 (en) | 2023-03-24 |
JP2022519370A (en) | 2022-03-23 |
CR20210458A (en) | 2021-11-04 |
HUE060905T2 (en) | 2023-04-28 |
PL3921028T3 (en) | 2023-02-13 |
WO2020161217A1 (en) | 2020-08-13 |
IL284983A (en) | 2021-09-30 |
RS63899B1 (en) | 2023-02-28 |
CL2021001934A1 (en) | 2022-04-01 |
SG11202108566VA (en) | 2021-09-29 |
LT3921028T (en) | 2023-02-10 |
ZA202106472B (en) | 2023-04-26 |
DK3921028T3 (en) | 2023-01-23 |
CN113677398A (en) | 2021-11-19 |
US20230406832A1 (en) | 2023-12-21 |
BR112021015060A2 (en) | 2021-10-05 |
HRP20230039T1 (en) | 2023-06-09 |
PE20212251A1 (en) | 2021-11-24 |
FI3921028T3 (en) | 2023-01-31 |
EP3921028A1 (en) | 2021-12-15 |
IL284983B1 (en) | 2024-03-01 |
KR20210126053A (en) | 2021-10-19 |
TW202045483A (en) | 2020-12-16 |
SI3921028T1 (en) | 2023-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021008981A (en) | Benzothiadiazepine compounds and their use as bile acid modulators. | |
MX2022006731A (en) | Benzothia(di)azepine compounds and their use as bile acid modulators. | |
ECSP22040834A (en) | BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | |
AR120676A1 (en) | BENZOTHI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILIARY ACID | |
CO2023016072A2 (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
EA201270666A1 (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING URIC ACID LEVEL | |
TW200716661A (en) | A novel triterpenic acid derivative and the skin external preparation containing the same | |
NZ598694A (en) | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | |
EA201101243A1 (en) | 3H-IMIDAZO [4,5-C] PIRIDIN-6-CARBOXAMIDE AS ANTI-INFLAMMATORY MEANS | |
DE602005021770D1 (en) | INDOLE-1-YL-ACETIC DERIVATIVES | |
BR112023010799A2 (en) | BENZOTIA(DI)AZEPINE COMPOUNDS AND THEIR USES AS BILLARY ACID MODULATORS | |
UA96441C2 (en) | Pharmaceutical composition comprosing thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease | |
EA200870216A1 (en) | AMIDO COMPOUNDS AND THEIR APPLICATION AS MEDICINES | |
NO20091488L (en) | Crystalline forms of 3- [5- (2-FHSorophenyl) - [1,2,4] oxadiazol-3-yl] benzoic acid | |
EP2091328A4 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
EA201171088A1 (en) | TREATMENT OF DISKINESIA IN DIFFERENT DISORDERS | |
SG151336A1 (en) | 1,3,4-oxadiazol-2-ones as ppar delta | |
NO20091182L (en) | 2 fenoksypyrimidinonanaloger | |
EA201590066A1 (en) | DIFTORGEXAHYDROCYCLOPENTAXOXASYNYLES AND DIFTORGEXAHYDROBENZOXASYNYLES AS BETA SECRETASE INHIBITORS | |
UA96794C2 (en) | Glucocorticoides, method of use thereof, treatment method and pharmaceutical formulation based thereon | |
WO2014036242A3 (en) | Benzothiazole or benzoxazole compounds as sumo activators | |
ATE507827T1 (en) | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS | |
CR20220278A (en) | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
EP1868613A4 (en) | Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine | |
NO20090067L (en) | Pharmaceutical combinations for the treatment of respiratory diseases |